Regeneron Pharmaceuticals, Inc. was established in 1988. It develops medicines for inflammatory, metabolic, and infectious diseases.
It was founded to research neurotrophic factors and how they regenerate. That’s how the company got its unique name.
Aflibercept, which is a VEGF inhibitor, was developed by Regeneron. This firm has also developed rilonacept, which is an interleukin-1 blocker. Regeneron also offers reliable medications for the growth of blood vessels and to soothe inflammation.
Bloomberg had revealed in 2012 that Regeneron was collaborating with Sanofi to develop a new cure to control cholesterol levels better than other drugs.
It would be up to 72% more effective than drugs introduced by competitor companies. The news was true and Regeneron collaborated with Sanofi in 2015.
These companies came together to research and develop new immune-oncology medicines. This collaboration helped Regeneron generate over $2 billion!
This company received a huge sum of money for developing REGN2810. That drug later became cemiplimab. Since Regeneron had offered a profitable return of 1,457%, it became the 7th best stock of the 2010s!
Regeneron is working with the US government to develop and produce antibody treatments. Even though some people had criticized that deal, it helped this company work on cures for diseases such as Coronavirus Disease.
This company is competing against some renowned pharmaceutical firms, which are as follows:
Headquarters: Cambridge, Massachusetts, U.S.
Founder(s): Phillip Allen Sharp, Kenneth Murray, Walter Gilbert, Heinz Schaller, Charles Weissmann
Year Founded: 1978
This biotechnology company has topped the list of companies with the best Culture Score! It delivers therapies for neurological disease cures and serves patients across the globe.
A group of prominent biologists from the leading American and European universities collaborated in 1978 to establish this firm. Two of them have received the Nobel Prize for DNA Sequencing and discovering Split Genes.
This company is ranked 388 among the world’s top 1000 brands. When compared with Regeneron, this company’s market cap is $42.46B. Regeneron on the other hand has a market cap of $49.52B!
Biogen discovers and delivers therapies for diseases, such as Alzheimer’s disease, hemophilia B, Multiple sclerosis, chronic lymphocytic leukemia, and several neurological health issues.
This company has over 9000 employees and it’s one of the most prominent competitors of Regeneron Pharmaceuticals!
Biogen’s revenue growth and margin performance are not as good as Regeneron has. This biotechnology company has returned only 2.3% and REGN has offered a whopping 58%!
Its performance during the post-covid period is not quite satisfying. That’s why the REGN stock is more alluring than BIIB!
RELATED: Companies similar to Cloudflare
2. Pfizer Inc
Headquarters: New York City, U.S.
Founder(s): Charles Pfizer, Charles F. Erhart
Year Founded: 1849
Pfizer is a world-famous pharmaceutical and biotechnology company. It has been developing and producing medicines and vaccines since 1849.
This company provides cures for oncology, immunology, cardiology, neurology, and endocrinology. Pfizer has launched numerous drugs to treat various diseases.
It generates over US$1 billion in revenue annually by selling medicines and vaccines in the USA, Japan, China, and many other countries.
It is ranked 64th among the Fortune 500 companies and that shows how popular it is among health experts and patients seeking a quality cure.
Pfizer has experienced a 106% growth in the fourth quarter of 2020 and Regeneron was right behind Pfizer with a 104% increase.
Being one of the oldest pharmaceutical firms, Pfizer Inc. is set to dominate the industry with its Covid pills. Experts believe that this firm will be the most dominant player in a $20 billion market!
Pfizer is going to sell its Covid pills across the globe. It will be able to supply large quantities of generic drugs by 2023.
Growing demands for Pfizer medicines will grow demands for its stocks. As a result, PFE will be a more lucrative stock than REGN.
Headquarters: Lake Bluff, Illinois, U.S.
Founder(s): Abbott Laboratories
Year Founded: 2013
AbbVie is a biopharmaceutical company. Abbott Laboratories announced in 2011 that it will operate as two separate publically traded companies. Thus, Abbvie was founded in January 2013 and now it trades as ABBV on the New York Stock Exchange.
AbbVie has spent about $50 billion to research and develop new drugs for various ailments. This company follows a dedicated approach to discovering new therapies and providing a better cure. It has 48,000 employees working across the globe to discover transformational medicines.
AbbVie provides therapeutic cures for oncology, immunology, neuroscience, virology, eye care, and health issues concerning women.
Both Regeneron and AbbVie have delivered satisfying fourth-quarter earnings. However, Regeneron has performed better due to its blockbuster EYLEA retinal disease drug.
AbbVie has also offered an amazing dividend yield of 4.9%. The ABBV stock is considered a high-yield stock. However, it has not received as much appreciation as the REGN stock has received.
Humira is the best-selling drug from this company, which has generated about 43% of the company’s total revenue.
Competitive drugs in the American and European markets pose a threat and they may cause a reduction in Humira’s demands!
4. Novartis AG
Headquarters: Basel, Switzerland
Founder(s): Johann Rudolf, Alexander Clavel
Year Founded: 1996
Being a multinational pharmaceutical corporation, Novartis produces clozapine, carbamazepine, diclofenac, valsartan, cyclosporine, imatinib mesylate, and many popular drugs.
This Swiss pharmaceutical company was founded in 1996 when Sandoz and Ciba-Geigy companies merged. Their pharmaceutical and agrochemical divisions became Novartis and today it operates as an independent firm.
Both Sandoz and Ciba-Geigy companies were sold, but Novartis revived both firms to run generic drugs and agrochemical businesses. Novartis became a major player in the pharmaceutical industry and a full member of EFPIA, IFPMA, and PhRMA.
Now, it is a Swiss holding company and it owns all the businesses operating as the Novartis Group subsidiaries. Innovative Medicines, Alcon, and Sandoz are the three main branches of this firm.
Those three branches are divided into several sub-branches that produce various drugs and medications.
Novartis’s annual revenue has significantly increased in 2021, which is $51.6B. It has experienced a $3 billion increase this year.
Regeneron has experienced 89% growth in its annual revenue, which is $16.072B. Regeneron has experienced much better growth than Novartis in 2021 and that trend may continue this year as well!
5. Bayer AG
Headquarters: Leverkusen, North Rhine-Westphalia, Germany
Founder(s): Friedrich Bayer
Year Founded: 1863
Bayer AG is one of the oldest pharmaceutical companies that produce consumer healthcare, pharmaceutical, biotechnology, and agricultural chemicals. This German firm has been in service since 1863.
Bayer used to be a dyestuffs producer during its early days. That changed when this company introduced the compound acetylsalicylic acid. That drug is commonly known as Aspirin today!
Phenobarbitol, heroin, polycarbonates, and polyurethanes are some other commonly known products commercialized by Bayer.
World War II severely damaged the image and business of this firm. It has played an important role in reconstructing the economy of Germany after the war.
It regained its position as one of the leading pharmaceutical companies in the world after 1951.
This German pharmaceutical firm currently employs 99,637 professionals across the globe. Kogenate, Xarelto, Yaz birth control pills, Betaseron, Nexavar, Rennie, Cipro, and Trysol are the best-selling drugs from this company.
It trades as BAYN and BAYRY on the world’s leading stock exchanges. It has continued to explore new cures and therefore its stock always lures investors.
Headquarters: Somerset, New Jersey, U.S.
Year Founded: 2007
Catalent, Inc. is a New Jersey-based company. It produces drugs for various diseases and develops drug delivery technologies, biologics, and gene therapy solutions.
Catalent Pharma Solutions has over 17,000 employees and over 2,400 of them are technicians and scientists.
This company has multi-modality manufacturing and top experts working on the development of delivery technologies.
Many organizations collaborate with Catalent to produce personalized consumer health products, medicines, and blockbuster drugs.
This company has been launching more than 150 new products annually. It has established manufacturing units on more than 50 global sites.
Catalent’s professional workforce produces more than 70 billion dosages of more than 7,000 products every year. It serves over 1,000 major clients and millions of individual clients.
This company’s annual revenue was $3 billion in 2020, which increased to $4 billion in 2021. Its stock value is continuously growing due to the cutting-edge solutions it is offering. When compared with Regeneron, Catalent is still quite new.
This firm has acquired several other companies, but it has not introduced any blockbuster drug as Bayer, Regeneron, Pfizer, and other global players did.
It is growing as a major pharma company if it manages to continue the growth trend year after year.
SUGGESTED: Companies similar to Roblox
7. Bristol Myers Squibb
Headquarters: New York, United States
Founder(s): William McLaren Bristol, John Ripley Myers, E. R. Squibb
Year Founded: 1887
Bristol Myers Squibb or BMS is a New York City-based multinational pharmaceutical firm. BMS produces biologics and prescriptions in many areas that include HIV/AIDS, cancer, diabetes, cardiovascular disease, rheumatoid arthritis, hepatitis, and psychiatric disorders.
This company frequently appears on the Fortune 500 list because it has emerged as one of the largest pharmaceutical companies in the world!
It has been serving for the last 135 years and it has introduced several life-saving drugs during this period. BMS has acquired several other companies to expand its reach and service area.
It hires the brightest professionals to develop innovative solutions for patients. Regeneron and BMS have been competing for many years and BMS has managed to capture a huge market.
This company has made noticeable advancements in hematology, oncology, cardiovascular disease, and immunology. It has invested a lot in new scientific research programs to develop better drugs than competitor firms.
Bristol Myers Squibb aims to develop life-changing treatments for chronic and dangerous diseases. New drugs and cures have helped BMS draw the attention of investors.
Thus, its assets and stock value continued to increase since the day it was established. Regeneron and BMS are tough competitors, but Regenero’s annual growth is way better than BMS!
Headquarters: Allschwil, BASEL-LAND, Switzerland
Founder(s): Jean-Paul Clozel
Year Founded: 2017
Idorsia is a Switzerland based biopharmaceutical company. It discovers, develops, and commercializes new cures to treat patients suffering from various diseases.
This firm has a diversified and well-managed clinical development pipeline. It covers several therapeutic areas, such as cardiovascular, CNS, and immunology disorders.
This company focuses on developing new compounds into reliable therapy. It is a complex process and Idorsia has some of the world’s leading scientists to observe and manage the development procedures.
It follows a scientific and data-driven approach to reduce the risk and increase the chances of success at each step. Thus, it releases at least three new products annually.
This company aims to serve as many patients as possible. Therefore, it has continued to build and incorporate a global commercial network.
This company is currently working on drugs to cure insomnia, Fabry disease, resistant hypertension management, systemic lupus erythematosus, cerebral vasospasm associated with aSAH, binge eating disorder, and acute myocardial infarction.
This company has employed 650 top-skilled professionals. It currently has 11 compounds in the pipeline and four of them are in the late stage of development.
It will soon launch some blockbuster drugs to help patients across the globe. The success of those drugs will also draw investors.
However, it may take time and Regeneron may introduce some more blockbuster drugs by that time!
Headquarters: Thousand Oaks, California, U.S.
Founder(s): George B. Rathmann
Year Founded: 1980
Amgen Inc. (Applied Molecular Genetics Inc.) is a U.S.-based biopharmaceutical company. It has emerged as one of the world’s leading biotechnology companies due to its innovative solutions!
It was founded in 1980 and its first recombinant human erythropoietin product, Epogen was launched in 1989.
This biopharmaceutical firm continued to research new compounds and find better cures for various diseases. It currently sells Neulasta, Enbrel, Epogen, Sensipar, Aranesp, Nplate, Prolia, Vectibix, and XGEV.
This company has employed over 5,000 professionals and it has established its research centers and manufacturing units in many countries.
This company supplies medicines across 100 countries and it is constantly expanding the service region to serve more patients. Amgen exists to offer better cures and support to treat some major diseases.
It is currently focusing on 6 therapeutic areas that include oncology, cardiovascular disease, neuroscience, bone health, inflammation, and nephrology. It has launched medicines for diseases, which have quite limited drugs!